High-performance liquid chromatographic-fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations

Analytical Biochemistry

Volumn 273, Issue 1, 1999, Pages 117-125

  Huang, Zeqi ^a   Waxman, David J ^a  

^a Boston University   (United States)

Author keywords

Chloroacetaldehyde; Cytochrome P450 metabolism; Ifosfamide N dechloroethylation

Indexed keywords

BIOMOLECULES; CATALYSIS; CHEMOTHERAPY; DRUG DOSAGE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM;

CHLOROACETALDEHYDE; CYTOCHROME P450; CYTOCHROME P450 ENZYMES; FLUORESCENCE DETECTION; FLUORESCENCE DETECTOR; FLUORESCENT METHODS; IFOSFAMIDE; INDIVIDUAL DIFFERENCES;

METABOLITES;

ACROLEIN; ADENOSINE; ADENOSINE DERIVATIVE; CHLOROACETALDEHYDE; CYTOCHROME P450; IFOSFAMIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROXYLATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME; MALE; METABOLISM; NEUROTOXICITY; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT;

EID: 0033566998     PISSN: 00032697     EISSN: None     Source Type: Journal    
DOI: 10.1006/abio.1999.4197     Document Type: Article

References (32)

1. Zalupski M., Baker L. H. J. Natl. Cancer Inst. 80:1988;556-566.
2. Brade W., Seeber S., Herdrich K. Cancer Chemother. Pharmacol. 18:1986;S1-S9.
3. Fleming R. A. Pharmacotherapy. 17:1997;146S-154S.
4. Kaijser G. P., Korst A., Beijnen J. H., Bult A., Underberg W. J. Anticancer Res. 13:1993;1311-1324.
5. Goren M. P., Wright R. K., Pratt C. B., Pell F. E. Lancet. 2:1986;1219-1220.
6. Skinner R., Sharkey I. M., Pearson A. D., Craft A. W. J. Clin. Oncol. 11:1993;173-190.
7. Boddy A. V., English M., Pearson A. D., Idle J. R., Skinner R. Eur. J. Cancer. 32A:1996;1179-1184.
8. Wainer I. W., Ducharme J., Granvil C. P., Trudeau M., Leyland-Jones B. Lancet. 343:1994;982-983.
9. Lind M. J., McGown A. T., Hadfield J. A., Thatcher N., Crowther D., Fox B. W. Biochem. Pharmacol. 38:1989;1835-1840.
10. Sood C., O'Brien P. J. Br. J. Cancer. 74:1996;S287-S293.
11. Springate J. E. J. Appl. Toxicol. 17:1997;75-79.
12. Pohl J., Stekar J., Hilgard P. Arzneimittelforschung. 39:1989;704-705.
13. McCann J., Simmon V., Streitwieser D., Ames B. N. Proc. Natl. Acad. Sci. USA. 72:1975;3190-3193.
14. Rinkus S. J., Legator M. S. Anal. Biochem. 150:1985;379-393.
15. Pandya G. A., Moriya M. Biochemistry. 35:1996;11487-11492.
16. Ruzicka J. A., Ruenitz P. C. J. Chromatogr. 518:1990;385-389.
17. Kaijser G. P., Beijnen J. H., Jeunink E. L., Bult A., Keizer H. J., de Kraker J., Underberg W. J. J. Chromatogr. 614:1993;253-259.
18. Brain E. G., Yu L. J., Gustafsson K., Drewes P., Waxman D. J. Br. J. Cancer. 77:1998;1768-1776.
19. Yu L., Waxman D. J. Drug Metab. Dispos. 24:1996;1254-1262.
20. Kurowski V., Wagner T. Cancer Chemother. Pharmacol. 33:1993;36-42.
21. Jacobson M. K., Hemingway L. M., Farrell T. A., Jones C. E. Am. J. Physiol. 245:1983;H887-H890.
22. Zhang Y., Geiger J. D., Lautt W. W. Am. J. Physiol. 260:1991;G658-G664.
23. Yu L. J., Drewes P., Gustafsson K., Brain E. G. C., Hecht J. E. D., Waxman D. J. J. Pharmacol. Exp. Ther. 288:1999;928-937.
24. Bohnenstengel F., Eichelbaum M., Golbs E., Kroemer H. K. J. Chromatogr. B Biomed. Sci. Appl. 692:1997;163-168.
25. Clarke L., Waxman D. J. Cancer Res. 49:1989;2344-2350.
26. Miura K., Okumura M., Yukimura T., Yamamoto K. Anal. Biochem. 196:1991;84-88.
27. Wojcik W. J., Neff N. H. J. Neurochem. 39:1982;280-282.
28. Slegel P., Kitagawa H., Maguire M. H. Anal. Biochem. 171:1988;124-134.
29. Fenton R. A., Dobson J. G. Jr. Anal. Biochem. 207:1992;134-141.
30. Kaijser G. P., Beijnen J. H., Bult A., Wiese G., de Kraker J., Keizer H. J., Underberg W. J. J. Chromatogr. 583:1992;175-182.
31. Jounaidi Y., Hecht J. E. D., Waxman D. J. Cancer Res. 58:1998;4391-4401.
32. Waxman D. J., Chen L., Hecht J. E. D., Jounaidi Y. Drug Metab. Rev. 31:1999;503-522.